Literature DB >> 2111051

Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1.

T Urano1, K Sakakibara, A Rydzewski, S Urano, Y Takada, A Takada.   

Abstract

The relationships between tissue plasminogen activator (tPA), its fast acting inhibitor (PAI-1) and euglobulin clot lysis time (ELT) were investigated with healthy volunteers' plasma. Turbidimetric clot lysis assay by the microtiter plate reader was utilized for ELT with a slight modification. Both tPA and PAI-1 showed the significant correlation with ELT. tPA had a significantly positive, not negative, correlation with ELT (R = 0.387, p less than 0.001). Higher correlation coefficients (R = 0.580, p less than 0.001 and R = 0.599, p less than 0.001) were obtained between ELT and total PAI-1 or free PAI-1 than tPA or tPA-PAI-1 complex (R = 0.427, p less than 0.001). The positive correlation was also obtained between tPA and PAI-1. These data suggest that PAI-1 is a highly important factor for ELT, especially, the amounts of free PAI-1 being the key factor to determine the ELT, which can represent the potential activity of the fibrinolytic system.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2111051

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  17 in total

1.  A case of late stent thrombosis following platelet transfusion in a patient with aplastic anemia.

Authors:  Hyun-Sung Shin; Tae Soo Kang
Journal:  Korean Circ J       Date:  2012-01-31       Impact factor: 3.243

2.  Profibrinolytic effect of Enzamin, an extract of metabolic products from Bacillus subtilis AK and Lactobacillus.

Authors:  Yukinori Tamura; Kiyotaka Okada; Naoyuki Kawao; Masato Yano; Shigeru Ueshima; Nobuo Nagai; Osamu Matsuo
Journal:  J Thromb Thrombolysis       Date:  2011-08       Impact factor: 2.300

3.  Plasma Concentration of Endogenous Tissue Plasminogen Activator and the Occurrence of Future Cardiovascular Events.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1994       Impact factor: 2.300

4.  Fibrinolytic activity in Nigerian diabetics.

Authors:  I A Adediran; R T Ikem; M F Borisade
Journal:  Postgrad Med J       Date:  2004-10       Impact factor: 2.401

5.  Risk factors for osteonecrosis of the femoral head in patients with sickle cell disease.

Authors:  A L Akinyoola; I A Adediran; C M Asaleye; A R Bolarinwa
Journal:  Int Orthop       Date:  2008-07-17       Impact factor: 3.075

6.  Tissue plasminogen activator, plasminogen activator inhibitor, and other parameters of fibrinolysis in the early stages of taurocholate acute pancreatitis in rats.

Authors:  G Rydzewska; S Kosidlo; A Gabryelewicz; A Rydzewski
Journal:  Int J Pancreatol       Date:  1992-06

7.  Circadian variation in fibrinolytic activity in patients with variant angina.

Authors:  T Masuda; H Ogawa; Y Miyao; Q Yu; I Misumi; T Sakamoto; H Okubo; K Okumura; H Yasue
Journal:  Br Heart J       Date:  1994-02

8.  Postoperative changes in plasma tissue-type plasminogen activator and type 1 plasminogen activator inhibitor.

Authors:  K Aoki; N Nishino; S Baba; T Urano; A Takada
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

9.  Exposure of endothelial cells to physiological levels of myeloperoxidase-modified LDL delays pericellular fibrinolysis.

Authors:  Karim Zouaoui Boudjeltia; Jalil Daher; Pierre Van Antwerpen; Nicole Moguilevsky; Paul Delree; Jean Ducobu; Martine Raes; Bassam Badran; Michel Vanhaeverbeek; Dany Brohee; Claude Remacle; Luc Vanhamme
Journal:  PLoS One       Date:  2012-06-19       Impact factor: 3.240

10.  A new device for measurement of fibrin clot lysis: application to the euglobulin clot lysis time.

Authors:  K Zouaoui Boudjeltia; Ph Cauchie; Cl Remacle; M Guillaume; D Brohée; J L Hubert; M Vanhaeverbeek
Journal:  BMC Biotechnol       Date:  2002-05-02       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.